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Abstract
Background:  Merkel cell carcinoma is a rare but aggressive cutaneous primary small cell
carcinoma. It is commonly seen in elderly affecting the head, neck, and extremities. Macroscopically
may be difficult to distinguish MCC from other small cells neoplasms especially oat cell carcinoma
of the lung.
Case presentation: It is presented a case report concerning a 72 years old male with a MMC on
the dorsal aspect of the right wrist. The patient underwent a diagnostic excisional biopsy and after
the histological confirmation of the diagnosis a second excision was performed to achieve free
margins. No postoperative radiation or adjuvant chemotherapy was given and within 9 years follow
up no recurrence was reported.
Conclusion: Although most cases present as localized disease treatment should be definitive due
to high rates of local or systemic recurrence. Treatment includes excision of the lesion,
lymphadenectomy, postoperative radiotherapy and chemotherapy depending on the stage of the
disease. Even when locoregional control is achieved close surveillance is required due to high rates
of relapse.
Background
Merkel cell carcinoma (MCC) is a rare cutaneous malig-
nancy that was first described by Toker in 1972 [1]. This
rare aggressive neoplasm is thought to originate from the
neurocrest derivatives round shaped Merkel cells located
in the basal layer of the epidermis and containing neuro-
secretory granules [2-5].
Although aetiology is not fully illuminated, there are sev-
eral risk factors that contribute to its pathogenesis. Those
include UV light, sun-related skin malignancies (Squa-
mous Cell Carcinoma, Basal Cell Carcinoma), psoriasis
treatment with methoxsalen and arsenic exposure.
Patients on immunosuppressive agents or patients with
diagnosis of AIDS, chronic lymphocytic leukemia, con-
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genital dysplasia syndrome and organ recipients carry a
higher risk as well [6-11].
Clinically, MCC appears as a painless, firm, non tender,
ulcerated skin lesion commonly less than 2 cm in size at
the time of presentation [4,8]. Most cases present as local-
ized disease (70%–80%) followed by regional lymph
node involvement (9%–26%) and distant metastasis
(1%–4%) [8]. These characteristics often raise the suspi-
cion of a skin malignancy but confirmation of diagnosis is
made by excisional biopsy. The differential diagnosis of
MCC from other small cells neoplasms can be difficult,
even on histological examination [10]. For definitive diag-
nosis in these cases, electron microscopy is necessary [5].
Case presentation
A 72-year-old male presented in December 1998 with a
painless nodular, red and firm 2 cm plaque located on the
dorsal aspect of the right wrist (Figure 1) noticed 1–2
months before. No history of previous skin lesions else-
where was reported.
An excisional biopsy was performed. Microscopical exam-
ination of the lesion revealed the invasion of dermis and
subcutaneous tissue by a small cell solid tumor with dif-
fuse pattern of infiltration (Figure 2). The excisional mar-
gins were positive although dermal lymphatics were intact
and no exceeding to the adjacent structures such us, veins,
tendons or nerves was discovered. The tumor cells were
small, with scanty acidophilic cytoplasm, round vescicu-
lar nuclei and multiple nucleoli (Figure 3). Mitotic figures
were numerous. In immunohistochemical examination,
the tumor cells showed diffuse positivity for Epithelial
Membrane Antigen (EMA, Figure 4) and Neuron Specific
Antigen (NSE, Figure 5). Lymphatic Common Antigen
(LCA), Thyroid Transcription Factor – 1 (TTF-1) and
CD99 were negative. Based on to these histological and
immunohistochemical features, diagnosis of Merkel Cell
Tumor was established.
The patient underwent an imaging evaluation with a CT
scan for staging. The CT did not reveal any masses, lym-
phadenopathy or distant metastases. An additional exci-
sion was performed in order to achieve approximately
margins 2–3 cm wide and 1–2 cm deep. The patient
expressed the willing not to receive postoperative radia-
tion or adjuvant chemotherapy which was justified based
on the stage of the disease and the cardiovascular and pul-
monary co-morbidities. We scheduled CT imaging follow
up every 6 months for the first 3 years and then annually
for the upcoming years. No recurrence was reported until
April 2007. (Figure 6).
Discussion
MMC is an aggressive neoplasm with an overall unfavour-
able prognosis [12], therefore it requires definite treat-
ment. It usually occurs in older patients with less than 5%
cases seen before the age of 50 years and it has an annual
incidence of 0.42 per 100.000. Both sexes are affected
with a male predominance, although in some series
higher incidence in women is reported [4,8,9]. Higher
likelihood is reported in whites and it affects sun exposed
areas such as head and neck (50%), upper and lower
limbs (35%–40%) and less than 10% in the trunk [8]. It
has also been reported that MMC rarely can occur on ana-
tomic sites such as vulva, penis, pharynx and oral or nasal
mucosa. [7].
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Macroscopically, MCC appears as a nodular, sometimes
ulcerated skin lesion with a reddish or violaceous hue
[12]. Microscopically, the tumor is centered in the dermis
or sometimes in the subcutaneous tissue, with the overly-
ing epidermis being usually not involved [13]. The tumor
cells are small and round, disposed in a diffuse or, rarely,
trabecular architectural pattern [14,15]. The cytoplasm is
scanty, visible as a thin eosinophilic rim. The nuclei are
round and vescicular, with a typically fine granular chro-
matin, multiple nucleoli and numerous mitotic figures.
The tumour stroma contains abundant vessels with hyper-
trophic endothelial cells. [15,16]
Immunohistochemically, the tumor cells are usually pos-
itive for low-molecular-weight cytokeratin (CK AE1), pre-
dominantly cytokeratin 20 (CK20) [17], neurofilaments
and NSE [18]. Additionally to these markers, some cases
of MCC have shown focal reactivity for chromogranin,
synaptophysin, vasoactive intestinal peptid, pancreatic
polypeptide, calcitonin, substance P, somatostatin,
ACTH, other peptide hormones and CD117. [19-24]
Differential diagnosis has to be made between MCC and
other small cell neoplasms (small cell neuroendocrine
lung carcinoma, malignant lymphoma, Ewing's sarcoma/
PNET category). Sometimes, tumors with an appearance
identical to pulmonary small cell neuroendocrine carci-
9 years post-op Figure 6
9 years post-op
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noma are found in the skin. [12] The consistent positivity
of the MCC for CD20 and the negativity for TTF-1 are
important in the differential diagnosis from small cell
neuroendocrine lung carcinoma [25-27]. The monoto-
nous nature of the dermal round cell infiltrate and the dif-
fuse pattern of infiltration are responsible for MCC's
misdiagnosis as malignant lymphoma [28]. Differential
diagnosis in this case is made using the immunohisto-
chemical lymphatic marker LCA. Finally, differential diag-
nosis of MCC from PNET is base on the negativity of the
neoplastic Merkel cells for CD99, positive in Ewing's sar-
coma/PNET [29].
The fact that MCC can be seen in association with in situ
or invasive SCC, with duct-like structures of eccrine type,
and with basal call carcinoma-like areas suggests that it
originates from a potential stem cell of ectodermal deriva-
tion. [30-33]
Chromosomal abnormalities localized on the short arm
of chromosome 1, associated with Merkel cell tumor are
common in melanoma and neuroblastoma. Chromo-
somal abnormalities (loss of heterozygosis in chromo-
some 3p21) associated with small cell lung
neuroendocrine carcinoma is related to Merkel cell carci-
noma as well. [8].
Due to its rarity and the lack of cases for a randomized
prospective trial no consensus of the appropriate treat-
ment protocol for MCC is made so far [6-8]. Therapeutic
options depend on the stage of the disease at the time of
presentation whereas the most important prognostic fac-
tor is the absence of nodal involvement [34].
Surgery remains the gold standard for localized disease
and is considered to be successful when margins 3 cm
wide and 2 cm deep are achieved [8,34]. Some contro-
versy exists showing that when the tumour size is less than
1.5–2 cm, obtaining margins less than 2–3 cm did not
lead to higher recurrences rates. [11] Mohs micrographic
surgery is an alternative method of wide clearance, espe-
cially on sites required excellent cosmetic results [6] and
some studies report better rates of locoregional control
[8,10,35,36]. A benefit of this method is the better inspec-
tion of all major borders of the lesion. [7,36]
Postoperative radiotherapy in node free patients either
discovered clinically, with imaging techniques, with a
negative sentinel node biopsy, or after routine nodal dis-
section still remains controversial. Due to the high rates of
local relapse, routine use of 45–60 Gy [8,10] to the area of
the lesion has been found to decrease local recurrence
[36]. Other series showed no significant difference com-
pared with surgery only [11] and distant metastasis and
overall survival seem to be similar compared to those who
did not receive radiation [10,37]. Postoperative radiother-
apy could be beneficial in cases of large primary tumours
or unattainable free surgical margins due to cosmetic or
functional difficulties [4,8] but radiating permanent mar-
gins did not yield satisfactory results [34].
Many authors advocate that lymph node recurrence often
represents the delayed manifestation of pre-existing occult
micrometastases rather than inadequate local control of
primary tumour [11]. Based on this, sentinel node biopsy
should be strongly considered. [11]. Involvement of the
regional lymph nodes decreases dramatically the survival
rates (88% to 50%) and it appears in 50%–70% of all
patients within 2 years by the time of diagnosis [38].
Other poor prognostic factors are tumour size >2 cm,
male sex, age >60 years, immunosuppression and loca-
tion on lower extremities [7-9,36]. Due to this high rate of
spreading, prophylactic nodal clearance of free disease
nodes is advocated in order to improve outcome. In some
studies sentinel node status was evaluated and a sentinel
node biopsy was performed in order to identify occult
micrometastases, showing low relapsing rates [6,11,38].
However, sentinel node biopsy is not attempted if addi-
tional therapy is not tolerated by the patient [11]. Based
on an another study it has been recommended prophylac-
tic lymphadenectomy only in patients with lesions
present for longer than 6 weeks prior seeking medical
advise or when tumour exceeds 1.5 cm in size. [10] Many
authors advocate the routine lymph node dissection,
including or not sentinel node biopsy [7,34] but others
conclude that routine lymph node dissection improves
locoregional control but has no effect on survival [39].
When nodal infiltration is established, definite manage-
ment includes complete lymphadenectomy and postoper-
ative radiotherapy. As a result of increased rate of
recurrence, even when lymph nodes have been removed,
strict follow-up is required. [8,10,38].
Disseminated disease whether primary or recurrent has a
very poor prognosis with an average expected survival of
8 months by the time of diagnosis. Imaging techniques
such as CT, MRI, PET scan and ocrteotide schintigraphy
have all been used to detect regional or distant metastases.
[7,11] Regional metastases are common, and distant
metastases can also occur, particularly in liver, bone, lung,
brain and skin. Rare cases of distant metastases of MCC in
bone marrow, pleura, testis, small bowel and stomach
have been reported [5,8,37]. Treatment in case of MCC
with distal metastases consists of palliative radiotherapy
and chemotherapy. Multiple agents have been used with
different response rates [38]. Those include cyclophos-
phamide, doxorubicin, etoposide, cis-platinum, vincris-
tine, methotrexate, 5-fluorouracile, carboplatinum [8,34].
Biologic agents such as interferon, tumour necrosis factorWorld Journal of Surgical Oncology 2008, 6:32 http://www.wjso.com/content/6/1/32
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(TNF) and imatinib mesylate promise better results on
local (TNF) or systemic control of MCC. [7] Radiotherapy
can be used as palliative therapy of cutaneous deposits or
bone and brain metastases [8]. Patients developing recur-
rence within the radiotherapy field are not candidates for
further high dose radiotherapy (>50 Gy) [9].
Conclusion
The overall 5-year survival rate for patients with Merkel
cell carcinoma is 50% to 68% [38]. Considering the high
incidence of local recurrence (27%–60%) regional node
involvement (45%–91%) or distant metastases (18%–
52%) [8], treatment should be definite with close follow
up. Despite the aggressiveness of MCC, early diagnosis,
optimal resection with clear margins and postoperative
radiotherapy achieve loco regional control of the tumor
and long term survival, although radiotherapy still
remains controversial [40]. In the cases of lymph node
involvement, prognosis is less favourable considering that
despite nodal dissection and adjuvant radiotherapy the
majority of patients will ultimately develop distant metas-
tases.
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